ARTICLE
15 February 2023

State Attorneys General Choose Sides In Legal Battle Over Abortion Drug Mifepristone

SG
Shipman & Goodwin LLP

Contributor

Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
An evenly split number of state attorneys general have picked sides in a legal battle taking place in federal court in the Northern District of Texas.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

An evenly split number of state attorneys general have picked sides in a legal battle taking place in federal court in the Northern District of Texas where Alliance for Hippocratic Medicine, et al., v. U.S. Food and Drug Administration, et al., 2:22-CV-00223 (U.S.D.C. Northern Dist. Texas, before J. Matthew Kacsmaryk) is seeking to have the FDA withdraw its 23-year-old approval of the abortion medication known as mifepristone (used with misoprostol). In fact, 22 Republican Attorneys General have filed an amicus brief in support of the challenge against the FDA and 22 Democratic Attorneys General filed an amicus brief in support of the FDA arguing that removal of FDA approval of mifepristone will have devastating consequences and result in more abortions occurring later in pregnancy.

As new developments arise, we will continue to update our Dobbs Decision Resource Center. In the meantime, please contact one of the lawyers in Shipman's Health Law practice group if you have questions about this ever-changing legal landscape.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
15 February 2023

State Attorneys General Choose Sides In Legal Battle Over Abortion Drug Mifepristone

United States Food, Drugs, Healthcare, Life Sciences

Contributor

Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More